Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Wants Clinically Meaningful Outcomes, Mortality Measured in IPF Trials

Executive Summary

Clinical trials for idiopathic pulmonary fibrosis should emphasize efficacy outcomes that are clinically meaningful to patients, and should measure mortality as a means of validating the endpoints chosen, an FDA official said, but exactly what those endpoints are is still uncertain

You may also be interested in...



Esbriet, Ofev Reviews Convinced FDA Of Acceptable IPF Endpoint

FDA leaders explain in NEJM how they came to accept a measure of lung function as a surrogate for mortality in trials of idiopathic pulmonary fibrosis therapies. See how agency reviewers handled this in a preview of our upcoming Drug Review Profile series.

Promedior Advances Novel Fibrotic Disease Therapy In Idiopathic Pulmonary Fibrosis

The start-up is also testing the ability of its monocyte-modulating approach to prevent scarring in glaucoma surgery.

Promedior Advances Novel Fibrotic Disease Therapy In Idiopathic Pulmonary Fibrosis

The start-up is also testing the ability of its monocyte-modulating approach to prevent scarring in glaucoma surgery.

Related Content

Topics

UsernamePublicRestriction

Register

PS052278

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel